ID   PIM1_HUMAN              Reviewed;         313 AA.
AC   P11309; Q38RT9; Q5T7H7; Q96RG3;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   10-OCT-2018, sequence version 4.
DT   12-OCT-2022, entry version 247.
DE   RecName: Full=Serine/threonine-protein kinase pim-1;
DE            EC=2.7.11.1;
GN   Name=PIM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=2205533; DOI=10.1016/0378-1119(90)90195-w;
RA   Reeves R., Spies G.A., Kiefer M., Barr P.J., Power M.;
RT   "Primary structure of the putative human oncogene, pim-1.";
RL   Gene 90:303-307(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3475233; DOI=10.1016/0378-1119(87)90352-0;
RA   Zakut-Houri R., Hazum S., Givol D., Telerman A.;
RT   "The cDNA sequence and gene analysis of the human pim oncogene.";
RL   Gene 54:105-111(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3329709;
RA   Domen J., von Lindern M., Hermans A., Breuer M., Grosveld G., Berns A.;
RT   "Comparison of the human and mouse PIM-1 cDNAs: nucleotide sequence and
RT   immunological identification of the in vitro synthesized PIM-1 protein.";
RL   Oncogene Res. 1:103-112(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3429489; DOI=10.1002/jcb.240350204;
RA   Meeker T.C., Nagarajan L., Ar-Rushdi A., Croce C.M.;
RT   "Cloning and characterization of the human PIM-1 gene: a putative oncogene
RT   related to the protein kinases.";
RL   J. Cell. Biochem. 35:105-112(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), ALTERNATIVE INITIATION, TISSUE
RP   SPECIFICITY, SUBCELLULAR LOCATION, INDUCTION, AND INTERACTION WITH BMX.
RX   PubMed=16186805; DOI=10.1038/sj.onc.1209058;
RA   Xie Y., Xu K., Dai B., Guo Z., Jiang T., Chen H., Qiu Y.;
RT   "The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX
RT   and protects human prostate cancer cells from apoptosis induced by
RT   chemotherapeutic drugs.";
RL   Oncogene 25:70-78(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-202 (ISOFORM 1).
RX   PubMed=11460166; DOI=10.1038/35085588;
RA   Pasqualucci L., Neumeister P., Goossens T., Nanjangud G., Chaganti R.S.K.,
RA   Kuppers R., Dalla-Favera R.;
RT   "Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell
RT   lymphomas.";
RL   Nature 412:341-346(2001).
RN   [10]
RP   CHARACTERIZATION.
RX   PubMed=2837645; DOI=10.1128/mcb.8.4.1498-1503.1988;
RA   Telerman A., Amson R., Zakut-Houri R., Givol D.;
RT   "Identification of the human pim-1 gene product as a 33-kilodalton
RT   cytoplasmic protein with tyrosine kinase activity.";
RL   Mol. Cell. Biol. 8:1498-1503(1988).
RN   [11]
RP   FUNCTION, AND ALTERNATIVE INITIATION.
RX   PubMed=1825810; DOI=10.1002/j.1460-2075.1991.tb07994.x;
RA   Saris C.J., Domen J., Berns A.;
RT   "The pim-1 oncogene encodes two related protein-serine/threonine kinases by
RT   alternative initiation at AUG and CUG.";
RL   EMBO J. 10:655-664(1991).
RN   [12]
RP   INTERACTION WITH CBX3, AND FUNCTION IN PHOSPHORYLATION OF CBX3.
RX   PubMed=10664448; DOI=10.1016/s0014-5793(00)01105-4;
RA   Koike N., Maita H., Taira T., Ariga H., Iguchi-Ariga S.M.M.;
RT   "Identification of heterochromatin protein 1 (HP1) as a phosphorylation
RT   target by Pim-1 kinase and the effect of phosphorylation on the
RT   transcriptional repression function of HP1.";
RL   FEBS Lett. 467:17-21(2000).
RN   [13]
RP   SUBCELLULAR LOCATION, FUNCTION IN PHOSPHORYLATION OF CDKN1A, AND
RP   INTERACTION WITH CDKN1A.
RX   PubMed=12431783; DOI=10.1016/s0167-4889(02)00347-6;
RA   Wang Z., Bhattacharya N., Mixter P.F., Wei W., Sedivy J., Magnuson N.S.;
RT   "Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1
RT   kinase.";
RL   Biochim. Biophys. Acta 1593:45-55(2002).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12680209;
RA   Ionov Y., Le X., Tunquist B.J., Sweetenham J., Sachs T., Ryder J.,
RA   Johnson T., Lilly M.B., Kraft A.S.;
RT   "Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear
RT   localization is necessary for its biologic effects.";
RL   Anticancer Res. 23:167-178(2003).
RN   [15]
RP   INTERACTION WITH PPP2CA, PHOSPHORYLATION, AND UBIQUITINATION.
RX   PubMed=12473674; DOI=10.1074/jbc.m208246200;
RA   Losman J.A., Chen X.P., Vuong B.Q., Fay S., Rothman P.B.;
RT   "Protein phosphatase 2A regulates the stability of Pim protein kinases.";
RL   J. Biol. Chem. 278:4800-4805(2003).
RN   [16]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=15528381; DOI=10.4049/jimmunol.173.10.6409;
RA   Stout B.A., Bates M.E., Liu L.Y., Farrington N.N., Bertics P.J.;
RT   "IL-5 and granulocyte-macrophage colony-stimulating factor activate STAT3
RT   and STAT5 and promote Pim-1 and cyclin D3 protein expression in human
RT   eosinophils.";
RL   J. Immunol. 173:6409-6417(2004).
RN   [17]
RP   UBIQUITINATION, INTERACTION WITH HSP90AA1 AND HSP70, AND INDUCTION.
RX   PubMed=15798097; DOI=10.1158/1541-7786.mcr-04-0192;
RA   Shay K.P., Wang Z., Xing P.X., McKenzie I.F., Magnuson N.S.;
RT   "Pim-1 kinase stability is regulated by heat shock proteins and the
RT   ubiquitin-proteasome pathway.";
RL   Mol. Cancer Res. 3:170-181(2005).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF CDC25C, AND INTERACTION WITH CDC25C.
RX   PubMed=16356754; DOI=10.1016/j.biocel.2005.10.010;
RA   Bachmann M., Kosan C., Xing P.X., Montenarh M., Hoffmann I., Moroy T.;
RT   "The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and
RT   activates the G2/M specific phosphatase Cdc25C.";
RL   Int. J. Biochem. Cell Biol. 38:430-443(2006).
RN   [19]
RP   FUNCTION IN CELL CYCLE PROGRESSION, INTERACTION WITH CDKN1B AND FOXO3, AND
RP   PHOSPHORYLATION OF CDKN1B AND FOXO3.
RX   PubMed=18593906; DOI=10.1158/0008-5472.can-08-0634;
RA   Morishita D., Katayama R., Sekimizu K., Tsuruo T., Fujita N.;
RT   "Pim kinases promote cell cycle progression by phosphorylating and down-
RT   regulating p27Kip1 at the transcriptional and posttranscriptional levels.";
RL   Cancer Res. 68:5076-5085(2008).
RN   [20]
RP   FUNCTION.
RX   PubMed=18056989; DOI=10.1074/jbc.m707773200;
RA   Xie Y., Xu K., Linn D.E., Yang X., Guo Z., Shimelis H., Nakanishi T.,
RA   Ross D.D., Chen H., Fazli L., Gleave M.E., Qiu Y.;
RT   "The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its
RT   multimerization and drug-resistant activity in human prostate cancer
RT   cells.";
RL   J. Biol. Chem. 283:3349-3356(2008).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF MAP3K5, AND INTERACTION WITH MAP3K5.
RX   PubMed=19749799; DOI=10.1038/onc.2009.276;
RA   Gu J.J., Wang Z., Reeves R., Magnuson N.S.;
RT   "PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis.";
RL   Oncogene 28:4261-4271(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-8, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 33-305 IN COMPLEXES WITH
RP   ADENOSINE AND INHIBITORS STAUROSPORINE AND LY294002, CATALYTIC ACTIVITY,
RP   COFACTOR, ACTIVITY REGULATION, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   PHOSPHORYLATION AT SER-8; THR-23; SER-98 AND SER-261.
RX   PubMed=15657054; DOI=10.1074/jbc.m413155200;
RA   Jacobs M.D., Black J., Futer O., Swenson L., Hare B., Fleming M.,
RA   Saxena K.;
RT   "Pim-1 ligand-bound structures reveal the mechanism of serine/threonine
RT   kinase inhibition by LY294002.";
RL   J. Biol. Chem. 280:13728-13734(2005).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 14-313 OF APOPROTEIN AND IN
RP   COMPLEX WITH AMP-PNP, CATALYTIC ACTIVITY, COFACTOR, AND ACTIVITY
RP   REGULATION.
RX   PubMed=15525646; DOI=10.1074/jbc.m409123200;
RA   Qian K.C., Wang L., Hickey E.R., Studts J., Barringer K., Peng C.,
RA   Kronkaitis A., Li J., White A., Mische S., Farmer B.;
RT   "Structural basis of constitutive activity and a unique nucleotide binding
RT   mode of human Pim-1 kinase.";
RL   J. Biol. Chem. 280:6130-6137(2005).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-313 OF APOPROTEIN AND IN
RP   COMPLEXES WITH AMP-PNP AND INHIBITORS, PARTIAL PROTEIN SEQUENCE, CATALYTIC
RP   ACTIVITY, ACTIVITY REGULATION, COFACTOR, AND MUTAGENESIS OF HIS-68; PRO-81;
RP   ASN-82 AND LEU-193.
RX   PubMed=15808862; DOI=10.1016/j.jmb.2005.02.039;
RA   Kumar A., Mandiyan V., Suzuki Y., Zhang C., Rice J., Tsai J., Artis D.R.,
RA   Ibrahim P., Bremer R.;
RT   "Crystal structures of proto-oncogene kinase Pim1: a target of aberrant
RT   somatic hypermutations in diffuse large cell lymphoma.";
RL   J. Mol. Biol. 348:183-193(2005).
RN   [26]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-53; GLN-124; LYS-135 AND ASP-142.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Proto-oncogene with serine/threonine kinase activity involved
CC       in cell survival and cell proliferation and thus providing a selective
CC       advantage in tumorigenesis. Exerts its oncogenic activity through: the
CC       regulation of MYC transcriptional activity, the regulation of cell
CC       cycle progression and by phosphorylation and inhibition of proapoptotic
CC       proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an
CC       increase of MYC protein stability and thereby an increase of
CC       transcriptional activity. The stabilization of MYC exerted by PIM1
CC       might explain partly the strong synergism between these two oncogenes
CC       in tumorigenesis. Mediates survival signaling through phosphorylation
CC       of BAD, which induces release of the anti-apoptotic protein Bcl-
CC       X(L)/BCL2L1. Phosphorylation of MAP3K5, another proapoptotic protein,
CC       by PIM1, significantly decreases MAP3K5 kinase activity and inhibits
CC       MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently
CC       reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle
CC       progression at the G1-S and G2-M transitions by phosphorylation of
CC       CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle
CC       progression at G1, results in the relocation of CDKN1A to the cytoplasm
CC       and enhanced CDKN1A protein stability. Promotes cell cycle progression
CC       and tumorigenesis by down-regulating expression of a regulator of cell
CC       cycle progression, CDKN1B, at both transcriptional and post-
CC       translational levels. Phosphorylation of CDKN1B, induces 14-3-3
CC       proteins binding, nuclear export and proteasome-dependent degradation.
CC       May affect the structure or silencing of chromatin by phosphorylating
CC       HP1 gamma/CBX3. Acts also as a regulator of homing and migration of
CC       bone marrow cells involving functional interaction with the CXCL12-
CC       CXCR4 signaling axis. Also phosphorylates and activates the ATP-binding
CC       cassette transporter ABCG2, allowing resistance to drugs through their
CC       excretion from cells (PubMed:18056989). Promotes brown adipocyte
CC       differentiation (By similarity). {ECO:0000250|UniProtKB:P06803,
CC       ECO:0000269|PubMed:10664448, ECO:0000269|PubMed:12431783,
CC       ECO:0000269|PubMed:15528381, ECO:0000269|PubMed:16356754,
CC       ECO:0000269|PubMed:18056989, ECO:0000269|PubMed:1825810,
CC       ECO:0000269|PubMed:18593906, ECO:0000269|PubMed:19749799}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:15525646, ECO:0000269|PubMed:15657054,
CC         ECO:0000269|PubMed:15808862};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:15525646,
CC         ECO:0000269|PubMed:15657054, ECO:0000269|PubMed:15808862};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:15525646, ECO:0000269|PubMed:15657054,
CC         ECO:0000269|PubMed:15808862};
CC   -!- SUBUNIT: Isoform 1 is isolated as a monomer whereas isoform 2 complexes
CC       with other proteins (By similarity). Binds to RP9 (By similarity).
CC       Isoform 2, but not isoform 1, binds BMX (PubMed:16186805). Isoform 1
CC       interacts with CDKN1B and FOXO3 (PubMed:18593906). Interacts with BAD
CC       (By similarity). Interacts with PPP2CA; this interaction promotes
CC       dephosphorylation of PIM1, ubiquitination and proteasomal degradation
CC       (PubMed:12473674). Interacts with HSP90AA1, this interaction stabilizes
CC       PIM1 protein levels. Interacts (ubiquitinated form) with HSP70 and
CC       promotes its proteosomal degradation (PubMed:15798097). Interacts with
CC       CDKN1A (PubMed:12431783). Interacts with CDC25C (PubMed:16356754).
CC       Interacts (via N-terminal 96 residues) with CDC25A (By similarity).
CC       Interacts with MAP3K5 (PubMed:19749799). Interacts with MYC (By
CC       similarity). Interacts with CBX3 (PubMed:10664448).
CC       {ECO:0000250|UniProtKB:P06803, ECO:0000269|PubMed:10664448,
CC       ECO:0000269|PubMed:12431783, ECO:0000269|PubMed:12473674,
CC       ECO:0000269|PubMed:15798097, ECO:0000269|PubMed:16186805,
CC       ECO:0000269|PubMed:16356754, ECO:0000269|PubMed:18593906,
CC       ECO:0000269|PubMed:19749799}.
CC   -!- INTERACTION:
CC       P11309; Q8N9N5: BANP; NbExp=3; IntAct=EBI-696621, EBI-744695;
CC       P11309; Q8N7W2-2: BEND7; NbExp=3; IntAct=EBI-696621, EBI-10181188;
CC       P11309; P51813: BMX; NbExp=2; IntAct=EBI-696621, EBI-696657;
CC       P11309; P07954: FH; NbExp=3; IntAct=EBI-696621, EBI-1050358;
CC       P11309; P51116: FXR2; NbExp=3; IntAct=EBI-696621, EBI-740459;
CC       P11309; Q96MH2: HEXIM2; NbExp=3; IntAct=EBI-696621, EBI-5460660;
CC       P11309; Q5T203: NHLH1; NbExp=3; IntAct=EBI-696621, EBI-10197511;
CC       P11309; P39019: RPS19; NbExp=7; IntAct=EBI-696621, EBI-354451;
CC       P11309; P0C1Z6-2: TFPT; NbExp=3; IntAct=EBI-696621, EBI-10178002;
CC       P11309; Q9Y2K1: ZBTB1; NbExp=3; IntAct=EBI-696621, EBI-2682961;
CC       P11309-1; P46527: CDKN1B; NbExp=2; IntAct=EBI-1018629, EBI-519280;
CC       P11309-1; O43524: FOXO3; NbExp=2; IntAct=EBI-1018629, EBI-1644164;
CC       P11309-1; Q9BZS1-1: FOXP3; NbExp=3; IntAct=EBI-1018629, EBI-9695448;
CC       P11309-2; Q9UNQ0: ABCG2; NbExp=5; IntAct=EBI-1018633, EBI-1569435;
CC       P11309-2; P51813: BMX; NbExp=6; IntAct=EBI-1018633, EBI-696657;
CC       P11309-2; P17252: PRKCA; NbExp=2; IntAct=EBI-1018633, EBI-1383528;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm. Nucleus.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1; Synonyms=Pim-1 {ECO:0000303|PubMed:18056989};
CC         IsoId=P11309-1; Sequence=Displayed;
CC       Name=2; Synonyms=Pim-1L {ECO:0000303|PubMed:18056989};
CC         IsoId=P11309-2; Sequence=VSP_059829;
CC   -!- TISSUE SPECIFICITY: Expressed primarily in cells of the hematopoietic
CC       and germline lineages. Isoform 1 and isoform 2 are both expressed in
CC       prostate cancer cell lines. {ECO:0000269|PubMed:16186805}.
CC   -!- INDUCTION: Strongly induced in leukocytes by the JAK/STAT pathway in
CC       response to cytokines. Induced by different cellular stresses, heat
CC       shock and cytotoxic agents. {ECO:0000269|PubMed:15528381,
CC       ECO:0000269|PubMed:15798097, ECO:0000269|PubMed:16186805}.
CC   -!- PTM: Autophosphorylated on both serine/threonine and tyrosine residues.
CC       Phosphorylated. Interaction with PPP2CA promotes dephosphorylation.
CC       {ECO:0000269|PubMed:12473674, ECO:0000269|PubMed:15657054,
CC       ECO:0000269|PubMed:18593906}.
CC   -!- PTM: Ubiquitinated, leading to proteasomal degradation.
CC       {ECO:0000269|PubMed:12473674, ECO:0000269|PubMed:15798097}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Initiates from CTG codon.
CC       {ECO:0000269|PubMed:16186805, ECO:0000269|PubMed:1825810}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. PIM subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PIM1ID261.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M27903; AAA60090.1; -; Genomic_DNA.
DR   EMBL; M16750; AAA60089.1; -; mRNA.
DR   EMBL; M54915; AAA36447.1; -; mRNA.
DR   EMBL; M24779; AAA81553.1; -; mRNA.
DR   EMBL; DQ022562; AAY87461.1; -; mRNA.
DR   EMBL; AL353579; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03934.1; -; Genomic_DNA.
DR   EMBL; BC020224; AAH20224.1; -; mRNA.
DR   EMBL; AF386792; AAK70871.1; -; Genomic_DNA.
DR   CCDS; CCDS4830.1; -. [P11309-1]
DR   PIR; JU0327; TVHUP1.
DR   RefSeq; NP_001230115.1; NM_001243186.1. [P11309-2]
DR   RefSeq; NP_002639.1; NM_002648.3. [P11309-1]
DR   PDB; 1XQZ; X-ray; 2.10 A; A=14-313.
DR   PDB; 1XR1; X-ray; 2.10 A; A=14-313.
DR   PDB; 1XWS; X-ray; 1.80 A; A=1-313.
DR   PDB; 1YHS; X-ray; 2.15 A; A=33-305.
DR   PDB; 1YI3; X-ray; 2.50 A; A=33-305.
DR   PDB; 1YI4; X-ray; 2.40 A; A=33-305.
DR   PDB; 1YWV; X-ray; 2.00 A; A=29-313.
DR   PDB; 1YXS; X-ray; 2.20 A; A=29-313.
DR   PDB; 1YXT; X-ray; 2.00 A; A=29-313.
DR   PDB; 1YXU; X-ray; 2.24 A; A/B/C/D=29-313.
DR   PDB; 1YXV; X-ray; 2.00 A; A=29-313.
DR   PDB; 1YXX; X-ray; 2.00 A; A=29-313.
DR   PDB; 2BIK; X-ray; 1.80 A; B=1-313.
DR   PDB; 2BIL; X-ray; 2.55 A; B=1-313.
DR   PDB; 2BZH; X-ray; 1.90 A; B=1-313.
DR   PDB; 2BZI; X-ray; 1.90 A; B=1-313.
DR   PDB; 2BZJ; X-ray; 2.05 A; A=1-313.
DR   PDB; 2BZK; X-ray; 2.45 A; B=1-313.
DR   PDB; 2C3I; X-ray; 1.90 A; B=1-313.
DR   PDB; 2J2I; X-ray; 1.90 A; B=1-312.
DR   PDB; 2O3P; X-ray; 2.24 A; A=29-313.
DR   PDB; 2O63; X-ray; 2.00 A; A=29-313.
DR   PDB; 2O64; X-ray; 2.44 A; A=29-313.
DR   PDB; 2O65; X-ray; 2.85 A; A=29-313.
DR   PDB; 2OBJ; X-ray; 2.50 A; A=1-313.
DR   PDB; 2OI4; X-ray; 2.20 A; X=1-313.
DR   PDB; 2XIX; X-ray; 2.40 A; A=14-313.
DR   PDB; 2XIY; X-ray; 2.20 A; A=14-313.
DR   PDB; 2XIZ; X-ray; 2.21 A; A=14-313.
DR   PDB; 2XJ0; X-ray; 3.10 A; A=14-313.
DR   PDB; 2XJ1; X-ray; 2.13 A; A=14-313.
DR   PDB; 2XJ2; X-ray; 2.20 A; A=14-313.
DR   PDB; 3A99; X-ray; 1.60 A; A=15-313.
DR   PDB; 3BGP; X-ray; 2.80 A; A=1-313.
DR   PDB; 3BGQ; X-ray; 2.00 A; A=1-313.
DR   PDB; 3BGZ; X-ray; 2.40 A; A=1-313.
DR   PDB; 3BWF; X-ray; 2.35 A; A=1-313.
DR   PDB; 3C4E; X-ray; 1.98 A; A/B/C/D=33-305.
DR   PDB; 3CXW; X-ray; 2.10 A; A=1-313.
DR   PDB; 3CY2; X-ray; 2.01 A; A=1-313.
DR   PDB; 3CY3; X-ray; 2.15 A; A=1-313.
DR   PDB; 3DCV; X-ray; 2.70 A; A=2-313.
DR   PDB; 3F2A; X-ray; 1.90 A; A=14-313.
DR   PDB; 3JPV; X-ray; 2.35 A; A=1-312.
DR   PDB; 3JXW; X-ray; 2.80 A; A=29-313.
DR   PDB; 3JY0; X-ray; 2.40 A; A=29-313.
DR   PDB; 3JYA; X-ray; 2.10 A; A=29-313.
DR   PDB; 3MA3; X-ray; 2.30 A; A=2-312.
DR   PDB; 3QF9; X-ray; 2.20 A; A=1-312.
DR   PDB; 3R00; X-ray; 2.10 A; A=29-313.
DR   PDB; 3R01; X-ray; 2.60 A; A=29-313.
DR   PDB; 3R02; X-ray; 1.95 A; A=29-313.
DR   PDB; 3R04; X-ray; 1.70 A; A=29-313.
DR   PDB; 3T9I; X-ray; 2.60 A; A=2-313.
DR   PDB; 3UIX; X-ray; 2.20 A; A=29-313.
DR   PDB; 3UMW; X-ray; 2.08 A; A=29-313.
DR   PDB; 3UMX; X-ray; 2.55 A; A=29-313.
DR   PDB; 3VBQ; X-ray; 1.85 A; A=29-313.
DR   PDB; 3VBT; X-ray; 2.23 A; A=29-313.
DR   PDB; 3VBV; X-ray; 2.08 A; A=29-313.
DR   PDB; 3VBW; X-ray; 2.48 A; A=29-313.
DR   PDB; 3VBX; X-ray; 2.03 A; A=29-313.
DR   PDB; 3VBY; X-ray; 2.27 A; A=29-313.
DR   PDB; 3VC4; X-ray; 2.23 A; A=29-313.
DR   PDB; 3WE8; X-ray; 1.95 A; A=33-305.
DR   PDB; 4A7C; X-ray; 2.30 A; A=30-313.
DR   PDB; 4ALU; X-ray; 2.60 A; A=2-313.
DR   PDB; 4ALV; X-ray; 2.59 A; A=2-313.
DR   PDB; 4ALW; X-ray; 1.92 A; A=2-313.
DR   PDB; 4AS0; X-ray; 2.30 A; A=33-305.
DR   PDB; 4BZN; X-ray; 1.90 A; A=2-313.
DR   PDB; 4BZO; X-ray; 2.10 A; A=2-313.
DR   PDB; 4DTK; X-ray; 1.86 A; A=30-305.
DR   PDB; 4ENX; X-ray; 2.80 A; A=29-313.
DR   PDB; 4ENY; X-ray; 2.80 A; A=29-313.
DR   PDB; 4GW8; X-ray; 2.00 A; A=1-312.
DR   PDB; 4I41; X-ray; 2.70 A; A=29-305.
DR   PDB; 4IAA; X-ray; 2.85 A; A=29-313.
DR   PDB; 4JX3; X-ray; 2.50 A; A=1-313.
DR   PDB; 4JX7; X-ray; 2.40 A; A=1-313.
DR   PDB; 4K0Y; X-ray; 1.95 A; A=33-306.
DR   PDB; 4K18; X-ray; 2.05 A; A=32-308.
DR   PDB; 4K1B; X-ray; 2.08 A; A=33-305.
DR   PDB; 4LL5; X-ray; 2.00 A; A=29-313.
DR   PDB; 4LM5; X-ray; 2.25 A; A=29-313.
DR   PDB; 4LMU; X-ray; 2.38 A; A=29-313.
DR   PDB; 4MBI; X-ray; 2.30 A; A=29-313.
DR   PDB; 4MBL; X-ray; 2.60 A; A=29-313.
DR   PDB; 4MTA; X-ray; 2.20 A; A=28-313.
DR   PDB; 4N6Y; X-ray; 2.60 A; A=2-313.
DR   PDB; 4N6Z; X-ray; 2.20 A; A=2-313.
DR   PDB; 4N70; X-ray; 2.10 A; A=2-313.
DR   PDB; 4RBL; X-ray; 2.55 A; A=29-313.
DR   PDB; 4RC2; X-ray; 2.10 A; A=29-313.
DR   PDB; 4RC3; X-ray; 2.34 A; A=29-313.
DR   PDB; 4RC4; X-ray; 2.65 A; A=29-313.
DR   PDB; 4RPV; X-ray; 3.05 A; A=1-313.
DR   PDB; 4TY1; X-ray; 2.70 A; A=33-305.
DR   PDB; 4WRS; X-ray; 2.20 A; A=33-305.
DR   PDB; 4WSY; X-ray; 2.30 A; A=33-305.
DR   PDB; 4WT6; X-ray; 2.30 A; A=33-305.
DR   PDB; 4XH6; X-ray; 2.04 A; A=29-313.
DR   PDB; 4XHK; X-ray; 1.90 A; B=1-313.
DR   PDB; 5C1Q; X-ray; 3.00 A; B=29-313.
DR   PDB; 5DGZ; X-ray; 2.50 A; A=29-313.
DR   PDB; 5DHJ; X-ray; 2.46 A; A=29-313.
DR   PDB; 5DIA; X-ray; 1.96 A; A=29-313.
DR   PDB; 5DWR; X-ray; 2.00 A; A=2-313.
DR   PDB; 5EOL; X-ray; 2.20 A; A=33-305.
DR   PDB; 5IIS; X-ray; 2.10 A; A=32-308.
DR   PDB; 5IPJ; X-ray; 2.10 A; A=33-305.
DR   PDB; 5KCX; X-ray; 2.20 A; A=29-313.
DR   PDB; 5KGD; X-ray; 1.98 A; A=30-305.
DR   PDB; 5KGE; X-ray; 2.23 A; A=30-305.
DR   PDB; 5KGG; X-ray; 1.95 A; A=30-305.
DR   PDB; 5KGI; X-ray; 2.13 A; A=30-305.
DR   PDB; 5KGK; X-ray; 2.66 A; A=30-305.
DR   PDB; 5KZI; X-ray; 2.10 A; A=33-305.
DR   PDB; 5MZL; X-ray; 1.96 A; A=1-313.
DR   PDB; 5N4N; X-ray; 2.09 A; A=1-313.
DR   PDB; 5N4O; X-ray; 2.22 A; A=1-313.
DR   PDB; 5N4R; X-ray; 2.13 A; A=1-313.
DR   PDB; 5N4U; X-ray; 2.20 A; A=1-313.
DR   PDB; 5N4V; X-ray; 1.85 A; A=1-313.
DR   PDB; 5N4X; X-ray; 2.20 A; A=1-313.
DR   PDB; 5N4Y; X-ray; 2.56 A; A=1-313.
DR   PDB; 5N4Z; X-ray; 2.26 A; A=1-313.
DR   PDB; 5N50; X-ray; 1.92 A; A=1-313.
DR   PDB; 5N51; X-ray; 2.12 A; A=1-313.
DR   PDB; 5N52; X-ray; 2.25 A; A=1-313.
DR   PDB; 5N5L; X-ray; 1.97 A; A=1-313.
DR   PDB; 5N5M; X-ray; 2.21 A; A=1-313.
DR   PDB; 5NDT; X-ray; 1.99 A; A=1-313.
DR   PDB; 5O11; X-ray; 2.40 A; A=29-313.
DR   PDB; 5O12; X-ray; 2.40 A; A=29-313.
DR   PDB; 5O13; X-ray; 2.44 A; A=29-313.
DR   PDB; 5TEL; X-ray; 2.21 A; A=33-306.
DR   PDB; 5TEX; X-ray; 2.15 A; A=33-306.
DR   PDB; 5TOE; X-ray; 2.30 A; A=34-306.
DR   PDB; 5TUR; X-ray; 2.95 A; A=1-313.
DR   PDB; 5V80; X-ray; 2.25 A; A=29-313.
DR   PDB; 5V82; X-ray; 1.89 A; A=29-313.
DR   PDB; 5VUA; X-ray; 2.20 A; B=29-313.
DR   PDB; 5VUB; X-ray; 2.00 A; B=29-313.
DR   PDB; 5VUC; X-ray; 2.00 A; B=29-313.
DR   PDB; 6AYD; X-ray; 3.00 A; A=1-312.
DR   PDB; 6BSK; X-ray; 2.57 A; A=30-305.
DR   PDB; 6KZI; X-ray; 2.80 A; A=29-313.
DR   PDB; 6L11; X-ray; 2.05 A; A=29-313.
DR   PDB; 6L12; X-ray; 1.87 A; A=29-313.
DR   PDB; 6L13; X-ray; 2.24 A; A=29-313.
DR   PDB; 6L14; X-ray; 1.95 A; A=29-313.
DR   PDB; 6L15; X-ray; 2.60 A; A=29-313.
DR   PDB; 6L16; X-ray; 2.10 A; A=29-313.
DR   PDB; 6L17; X-ray; 1.75 A; A=29-313.
DR   PDB; 6MT0; X-ray; 2.20 A; A=33-305.
DR   PDB; 6NO8; X-ray; 2.38 A; A=33-305.
DR   PDB; 6NO9; X-ray; 1.71 A; A=33-305.
DR   PDB; 6PCW; X-ray; 2.20 A; A=1-312.
DR   PDB; 6PDI; X-ray; 1.85 A; A=1-312.
DR   PDB; 6PDN; X-ray; 2.40 A; A=1-312.
DR   PDB; 6PDO; X-ray; 2.40 A; A=1-312.
DR   PDB; 6PDP; X-ray; 2.50 A; A=1-312.
DR   PDB; 6QXK; X-ray; 2.10 A; B=1-312.
DR   PDB; 6VRU; X-ray; 2.07 A; A=33-306.
DR   PDB; 6VRV; X-ray; 1.74 A; A=33-306.
DR   PDB; 6YKD; X-ray; 1.86 A; A=1-313.
DR   PDB; 7OOV; X-ray; 1.96 A; A=1-312.
DR   PDB; 7OOW; X-ray; 1.95 A; A=1-312.
DR   PDB; 7OOX; X-ray; 1.97 A; A=1-312.
DR   PDBsum; 1XQZ; -.
DR   PDBsum; 1XR1; -.
DR   PDBsum; 1XWS; -.
DR   PDBsum; 1YHS; -.
DR   PDBsum; 1YI3; -.
DR   PDBsum; 1YI4; -.
DR   PDBsum; 1YWV; -.
DR   PDBsum; 1YXS; -.
DR   PDBsum; 1YXT; -.
DR   PDBsum; 1YXU; -.
DR   PDBsum; 1YXV; -.
DR   PDBsum; 1YXX; -.
DR   PDBsum; 2BIK; -.
DR   PDBsum; 2BIL; -.
DR   PDBsum; 2BZH; -.
DR   PDBsum; 2BZI; -.
DR   PDBsum; 2BZJ; -.
DR   PDBsum; 2BZK; -.
DR   PDBsum; 2C3I; -.
DR   PDBsum; 2J2I; -.
DR   PDBsum; 2O3P; -.
DR   PDBsum; 2O63; -.
DR   PDBsum; 2O64; -.
DR   PDBsum; 2O65; -.
DR   PDBsum; 2OBJ; -.
DR   PDBsum; 2OI4; -.
DR   PDBsum; 2XIX; -.
DR   PDBsum; 2XIY; -.
DR   PDBsum; 2XIZ; -.
DR   PDBsum; 2XJ0; -.
DR   PDBsum; 2XJ1; -.
DR   PDBsum; 2XJ2; -.
DR   PDBsum; 3A99; -.
DR   PDBsum; 3BGP; -.
DR   PDBsum; 3BGQ; -.
DR   PDBsum; 3BGZ; -.
DR   PDBsum; 3BWF; -.
DR   PDBsum; 3C4E; -.
DR   PDBsum; 3CXW; -.
DR   PDBsum; 3CY2; -.
DR   PDBsum; 3CY3; -.
DR   PDBsum; 3DCV; -.
DR   PDBsum; 3F2A; -.
DR   PDBsum; 3JPV; -.
DR   PDBsum; 3JXW; -.
DR   PDBsum; 3JY0; -.
DR   PDBsum; 3JYA; -.
DR   PDBsum; 3MA3; -.
DR   PDBsum; 3QF9; -.
DR   PDBsum; 3R00; -.
DR   PDBsum; 3R01; -.
DR   PDBsum; 3R02; -.
DR   PDBsum; 3R04; -.
DR   PDBsum; 3T9I; -.
DR   PDBsum; 3UIX; -.
DR   PDBsum; 3UMW; -.
DR   PDBsum; 3UMX; -.
DR   PDBsum; 3VBQ; -.
DR   PDBsum; 3VBT; -.
DR   PDBsum; 3VBV; -.
DR   PDBsum; 3VBW; -.
DR   PDBsum; 3VBX; -.
DR   PDBsum; 3VBY; -.
DR   PDBsum; 3VC4; -.
DR   PDBsum; 3WE8; -.
DR   PDBsum; 4A7C; -.
DR   PDBsum; 4ALU; -.
DR   PDBsum; 4ALV; -.
DR   PDBsum; 4ALW; -.
DR   PDBsum; 4AS0; -.
DR   PDBsum; 4BZN; -.
DR   PDBsum; 4BZO; -.
DR   PDBsum; 4DTK; -.
DR   PDBsum; 4ENX; -.
DR   PDBsum; 4ENY; -.
DR   PDBsum; 4GW8; -.
DR   PDBsum; 4I41; -.
DR   PDBsum; 4IAA; -.
DR   PDBsum; 4JX3; -.
DR   PDBsum; 4JX7; -.
DR   PDBsum; 4K0Y; -.
DR   PDBsum; 4K18; -.
DR   PDBsum; 4K1B; -.
DR   PDBsum; 4LL5; -.
DR   PDBsum; 4LM5; -.
DR   PDBsum; 4LMU; -.
DR   PDBsum; 4MBI; -.
DR   PDBsum; 4MBL; -.
DR   PDBsum; 4MTA; -.
DR   PDBsum; 4N6Y; -.
DR   PDBsum; 4N6Z; -.
DR   PDBsum; 4N70; -.
DR   PDBsum; 4RBL; -.
DR   PDBsum; 4RC2; -.
DR   PDBsum; 4RC3; -.
DR   PDBsum; 4RC4; -.
DR   PDBsum; 4RPV; -.
DR   PDBsum; 4TY1; -.
DR   PDBsum; 4WRS; -.
DR   PDBsum; 4WSY; -.
DR   PDBsum; 4WT6; -.
DR   PDBsum; 4XH6; -.
DR   PDBsum; 4XHK; -.
DR   PDBsum; 5C1Q; -.
DR   PDBsum; 5DGZ; -.
DR   PDBsum; 5DHJ; -.
DR   PDBsum; 5DIA; -.
DR   PDBsum; 5DWR; -.
DR   PDBsum; 5EOL; -.
DR   PDBsum; 5IIS; -.
DR   PDBsum; 5IPJ; -.
DR   PDBsum; 5KCX; -.
DR   PDBsum; 5KGD; -.
DR   PDBsum; 5KGE; -.
DR   PDBsum; 5KGG; -.
DR   PDBsum; 5KGI; -.
DR   PDBsum; 5KGK; -.
DR   PDBsum; 5KZI; -.
DR   PDBsum; 5MZL; -.
DR   PDBsum; 5N4N; -.
DR   PDBsum; 5N4O; -.
DR   PDBsum; 5N4R; -.
DR   PDBsum; 5N4U; -.
DR   PDBsum; 5N4V; -.
DR   PDBsum; 5N4X; -.
DR   PDBsum; 5N4Y; -.
DR   PDBsum; 5N4Z; -.
DR   PDBsum; 5N50; -.
DR   PDBsum; 5N51; -.
DR   PDBsum; 5N52; -.
DR   PDBsum; 5N5L; -.
DR   PDBsum; 5N5M; -.
DR   PDBsum; 5NDT; -.
DR   PDBsum; 5O11; -.
DR   PDBsum; 5O12; -.
DR   PDBsum; 5O13; -.
DR   PDBsum; 5TEL; -.
DR   PDBsum; 5TEX; -.
DR   PDBsum; 5TOE; -.
DR   PDBsum; 5TUR; -.
DR   PDBsum; 5V80; -.
DR   PDBsum; 5V82; -.
DR   PDBsum; 5VUA; -.
DR   PDBsum; 5VUB; -.
DR   PDBsum; 5VUC; -.
DR   PDBsum; 6AYD; -.
DR   PDBsum; 6BSK; -.
DR   PDBsum; 6KZI; -.
DR   PDBsum; 6L11; -.
DR   PDBsum; 6L12; -.
DR   PDBsum; 6L13; -.
DR   PDBsum; 6L14; -.
DR   PDBsum; 6L15; -.
DR   PDBsum; 6L16; -.
DR   PDBsum; 6L17; -.
DR   PDBsum; 6MT0; -.
DR   PDBsum; 6NO8; -.
DR   PDBsum; 6NO9; -.
DR   PDBsum; 6PCW; -.
DR   PDBsum; 6PDI; -.
DR   PDBsum; 6PDN; -.
DR   PDBsum; 6PDO; -.
DR   PDBsum; 6PDP; -.
DR   PDBsum; 6QXK; -.
DR   PDBsum; 6VRU; -.
DR   PDBsum; 6VRV; -.
DR   PDBsum; 6YKD; -.
DR   PDBsum; 7OOV; -.
DR   PDBsum; 7OOW; -.
DR   PDBsum; 7OOX; -.
DR   AlphaFoldDB; P11309; -.
DR   SMR; P11309; -.
DR   BioGRID; 111310; 67.
DR   IntAct; P11309; 38.
DR   MINT; P11309; -.
DR   STRING; 9606.ENSP00000362608; -.
DR   BindingDB; P11309; -.
DR   ChEMBL; CHEMBL2147; -.
DR   DrugBank; DB08022; (2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile.
DR   DrugBank; DB03650; (3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One.
DR   DrugBank; DB07242; (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile.
DR   DrugBank; DB08166; (4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile.
DR   DrugBank; DB08709; 2,3-diphenyl-1H-indole-7-carboxylic acid.
DR   DrugBank; DB01754; 3,4-Dihydroxy-1-Methylquinolin-2(1h)-One.
DR   DrugBank; DB07151; 4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one.
DR   DrugBank; DB08707; 4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine.
DR   DrugBank; DB08705; 6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE.
DR   DrugBank; DB03777; Bisindolylmaleimide I.
DR   DrugBank; DB04522; Dexfosfoserine.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB03366; Imidazole.
DR   DrugBank; DB04715; IMIDAZOPYRIDAZIN 1.
DR   DrugBank; DB02656; LY-294002.
DR   DrugBank; DB08708; N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine.
DR   DrugBank; DB07524; N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB04216; Quercetin.
DR   DrugBank; DB04530; S,S-(2-Hydroxyethyl)Thiocysteine.
DR   DrugBank; DB02010; Staurosporine.
DR   DrugBank; DB08230; Tricetin.
DR   DrugCentral; P11309; -.
DR   GuidetoPHARMACOLOGY; 2158; -.
DR   GlyGen; P11309; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P11309; -.
DR   PhosphoSitePlus; P11309; -.
DR   BioMuta; PIM1; -.
DR   DMDM; 83305339; -.
DR   EPD; P11309; -.
DR   jPOST; P11309; -.
DR   MassIVE; P11309; -.
DR   MaxQB; P11309; -.
DR   PaxDb; P11309; -.
DR   PeptideAtlas; P11309; -.
DR   PRIDE; P11309; -.
DR   ProteomicsDB; 52741; -. [P11309-1]
DR   ProteomicsDB; 52742; -. [P11309-2]
DR   Antibodypedia; 1207; 727 antibodies from 37 providers.
DR   DNASU; 5292; -.
DR   Ensembl; ENST00000373509.6; ENSP00000362608.5; ENSG00000137193.14. [P11309-1]
DR   GeneID; 5292; -.
DR   KEGG; hsa:5292; -.
DR   MANE-Select; ENST00000373509.6; ENSP00000362608.5; NM_002648.4; NP_002639.1.
DR   UCSC; uc003onk.4; human. [P11309-1]
DR   CTD; 5292; -.
DR   DisGeNET; 5292; -.
DR   GeneCards; PIM1; -.
DR   HGNC; HGNC:8986; PIM1.
DR   HPA; ENSG00000137193; Tissue enhanced (bone).
DR   MIM; 164960; gene.
DR   neXtProt; NX_P11309; -.
DR   OpenTargets; ENSG00000137193; -.
DR   PharmGKB; PA33318; -.
DR   VEuPathDB; HostDB:ENSG00000137193; -.
DR   eggNOG; KOG0583; Eukaryota.
DR   GeneTree; ENSGT00940000153394; -.
DR   HOGENOM; CLU_000288_63_0_1; -.
DR   InParanoid; P11309; -.
DR   OMA; QDIHLEP; -.
DR   OrthoDB; 930292at2759; -.
DR   PhylomeDB; P11309; -.
DR   TreeFam; TF320810; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; P11309; -.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-9702518; STAT5 activation downstream of FLT3 ITD mutants.
DR   Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins.
DR   SignaLink; P11309; -.
DR   SIGNOR; P11309; -.
DR   BioGRID-ORCS; 5292; 39 hits in 1115 CRISPR screens.
DR   ChiTaRS; PIM1; human.
DR   EvolutionaryTrace; P11309; -.
DR   GeneWiki; PIM1; -.
DR   GenomeRNAi; 5292; -.
DR   Pharos; P11309; Tchem.
DR   PRO; PR:P11309; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P11309; protein.
DR   Bgee; ENSG00000137193; Expressed in lower esophagus mucosa and 177 other tissues.
DR   ExpressionAtlas; P11309; baseline and differential.
DR   Genevisible; P11309; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IMP:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0043024; F:ribosomal small subunit binding; IPI:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:1990748; P:cellular detoxification; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0043433; P:negative regulation of DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0090336; P:positive regulation of brown fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:1905062; P:positive regulation of cardioblast proliferation; IDA:BHF-UCL.
DR   GO; GO:0045737; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IEA:Ensembl.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IEA:Ensembl.
DR   GO; GO:1902033; P:regulation of hematopoietic stem cell proliferation; IEA:Ensembl.
DR   GO; GO:0022898; P:regulation of transmembrane transporter activity; IMP:UniProtKB.
DR   GO; GO:0070561; P:vitamin D receptor signaling pathway; IMP:CACAO.
DR   DisProt; DP00322; -.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017348; PIM1/2/3.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF037993; STPK_Pim-1; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Apoptosis; ATP-binding; Cell cycle;
KW   Cell membrane; Cytoplasm; Direct protein sequencing; Kinase; Magnesium;
KW   Membrane; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Proto-oncogene; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Ubl conjugation.
FT   CHAIN           1..313
FT                   /note="Serine/threonine-protein kinase pim-1"
FT                   /id="PRO_0000043349"
FT   DOMAIN          38..290
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        167
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         44..52
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         67
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         121
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         128
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         8
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15657054,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         23
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:15657054"
FT   MOD_RES         98
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15657054"
FT   MOD_RES         261
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15657054"
FT   VAR_SEQ         1
FT                   /note="M -> MPHEPHEPLTPPFSALPDPAGAPSRRQSRQRPQLSSDSPSAFRASRS
FT                   HSRNATRSHSHSHSPRHSLRHSPGSGSCGSSSGHRPCADILEVGM (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:16186805"
FT                   /id="VSP_059829"
FT   VARIANT         53
FT                   /note="Y -> H (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041004"
FT   VARIANT         124
FT                   /note="E -> Q (in dbSNP:rs35760989)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041005"
FT   VARIANT         135
FT                   /note="E -> K (in dbSNP:rs200523275)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041006"
FT   VARIANT         142
FT                   /note="E -> D (in dbSNP:rs33989191)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041007"
FT   MUTAGEN         68
FT                   /note="H->Y: Increased kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15808862"
FT   MUTAGEN         81
FT                   /note="P->S: Decreased kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15808862"
FT   MUTAGEN         82
FT                   /note="N->K: Decreased kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15808862"
FT   MUTAGEN         193
FT                   /note="L->F: Decreased kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15808862"
FT   CONFLICT        15..16
FT                   /note="AP -> RA (in Ref. 2; AAA60089)"
FT                   /evidence="ECO:0000305"
FT   TURN            6..9
FT                   /evidence="ECO:0007829|PDB:7OOX"
FT   STRAND          10..12
FT                   /evidence="ECO:0007829|PDB:7OOX"
FT   TURN            35..37
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   STRAND          38..43
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   STRAND          45..49
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   STRAND          51..57
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   TURN            58..60
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   STRAND          63..70
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           71..73
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   STRAND          77..79
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   TURN            81..83
FT                   /evidence="ECO:0007829|PDB:3C4E"
FT   STRAND          85..87
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           88..96
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   STRAND          98..100
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   STRAND          101..103
FT                   /evidence="ECO:0007829|PDB:3VBQ"
FT   STRAND          106..111
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   STRAND          113..121
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   STRAND          124..128
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           129..136
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           141..160
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           170..172
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   STRAND          173..176
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   TURN            177..180
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   STRAND          181..184
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           187..189
FT                   /evidence="ECO:0007829|PDB:4ALW"
FT   HELIX           205..207
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           210..215
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           220..237
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           245..250
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           261..270
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           275..277
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           281..285
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           288..290
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   HELIX           296..303
FT                   /evidence="ECO:0007829|PDB:3A99"
FT   TURN            304..307
FT                   /evidence="ECO:0007829|PDB:3F2A"
SQ   SEQUENCE   313 AA;  35686 MW;  35BA76D3668E69A3 CRC64;
     MLLSKINSLA HLRAAPCNDL HATKLAPGKE KEPLESQYQV GPLLGSGGFG SVYSGIRVSD
     NLPVAIKHVE KDRISDWGEL PNGTRVPMEV VLLKKVSSGF SGVIRLLDWF ERPDSFVLIL
     ERPEPVQDLF DFITERGALQ EELARSFFWQ VLEAVRHCHN CGVLHRDIKD ENILIDLNRG
     ELKLIDFGSG ALLKDTVYTD FDGTRVYSPP EWIRYHRYHG RSAAVWSLGI LLYDMVCGDI
     PFEHDEEIIR GQVFFRQRVS SECQHLIRWC LALRPSDRPT FEEIQNHPWM QDVLLPQETA
     EIHLHSLSPG PSK
//
